Prevention of needle displacement in multifraction high-dose-rate prostate brachytherapy: A prospective volumetric analysis and technical considerations - Abstract

PURPOSE: We conducted a prospective study to evaluate needle displacements between prostate high-dose-rate (HDR) brachytherapy fractions and offer technical recommendations to help prevent displacements from the outset.

METHODS AND MATERIALS: Planning computed tomography and verification computed tomography scans were obtained at 1-mm slice thickness and prospectively assessed for interfraction needle movement for each fraction of a 2-fraction HDR prostate boost. For both the planning and verification CTs, distances from each needle tip to the centroid of 3 implanted prostate gold seeds were measured. We determined the mean and range of the displacement distances.

RESULTS: Thirty-three consecutive patients (66 fractions, 540 needle-pair positions for a total of 1080 needles) were evaluated for changes in the length between the needle tip and centroid displacement. Overall, only 0.2% of the needles had any change greater than 3.5 mm between the needle tip and centroid. The mean amount of displacement was 0.97 mm, with a standard deviation of 0.76 mm. Among the patients, no fraction had more than 1 needle with a variation greater than 3.0 mm.

CONCLUSIONS: Needle displacements in HDR prostate brachytherapy have been reported by numerous institutions using various techniques. We report the first study to demonstrate needle displacement of less than 1 mm on average, and we describe our process of care surrounding the implantation.

Written by:
Peddada AV, Blasi OC, White GA, Monroe AT, Jennings SB, Gibbs GL.   Are you the author?
Penrose Cancer Center, Radiation Oncology, Colorado Springs, Colorado; Penrose Cancer Center, Colorado Associates in Medical Physics, Colorado Springs, Colorado; Colorado Springs Health Partners, Urology, Colorado Springs, Colorado.

Reference: Pract Radiat Oncol. 2014 Dec 24. pii: S1879-8500(14)00316-6.
doi: 10.1016/j.prro.2014.11.004

PubMed Abstract
PMID: 25543199 Prostate Cancer Section